13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001633313
Total reported value
$11.1B
$11.1B
39 檔
31.2%
At the close of Q4 2024, Avoro Capital Advisors LLC disclosed equity holdings valued at approximately $11.1B, spread across 39 reported holdings.
In Q4 2024, Avoro Capital Advisors LLC displayed an active expansion posture, initiating 7 new positions and adding to 10 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, ARGX, ASND) accounted for 31.2% of total reported equity market value during Q4 2024.
Top New Position Initiated
2655787D
市值: $103.4M
Top Position Liquidated / Trimmed
DYN
前期市值: $23.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 13.78% | -1.92% | -3.45% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 10.77% | +1.15% | — | |
| 3 | ASND | Ascendis Pharma A/S | Stock-Other | 9.94% | -11.39% | EXIT | |
| 4 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 8.86% | -0.52% | — | |
| 5 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 5.83% | +2.30% | +0.25% | |
| 6 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 5.52% | -4.84% | EXIT | |
| 7 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 4.40% | — | — | |
| 8 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.60% | — | — | |
| 9 | VERA | Vera Therapeutics Inc | Stock-Other | 3.36% | -0.12% | +30.17% | |
| 10 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.14% | -0.18% | — | |
| 11 | AM6 | Amicus Therapeutics Inc | Stock-Other | 3.09% | — | — | |
| 12 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.08% | — | +9.09% | |
| 13 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.95% | +1.71% | +25.00% | |
| 14 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.93% | +1.58% | +14.44% | |
| 15 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.12% | — | — | |
| 16 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.61% | -0.76% | EXIT | |
| 17 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.46% | — | — | |
| 18 | PCVX | Vaxcyte Inc | Stock-Other | 1.36% | — | — | |
| 19 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.36% | — | -28.24% | |
| 20 | ✓ | Merus N V | Stock-Other | 1.26% | — | +56.83% | |
| 21 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.26% | — | — | |
| 22 | ALKS | Alkermes plc | Stock-Healthcare | 1.00% | -0.42% | EXIT | |
| 23 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.97% | +0.08% | — | |
| 24 | MNKD | Mannkind CORP | Stock-Other | 0.80% | -0.05% | EXIT | |
| 25 | TRML | Tourmaline Bio Inc | Stock-Other | 0.64% | — | — | |
| 26 | QURE | uniQure N.V. | Stock-Other | 0.54% | +1.82% | — | |
| 27 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.49% | — | — | |
| 28 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.49% | +0.51% | +7.24% | |
| 29 | ETNBGBP | 89bio Inc | Stock-Other | 0.45% | — | — | |
| 30 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.43% | — | -24.96% | |
| 31 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.43% | — | -41.49% | |
| 32 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 0.37% | — | -17.45% | |
| 33 | SEPN | Septerna Inc | Stock-Other | 0.36% | +0.08% | — | |
| 34 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.33% | — | -19.72% | |
| 35 | CGON | Cg Oncology Inc | Stock-Other | 0.28% | — | — | |
| 36 | KURA | Kura Oncology Inc | Stock-Other | 0.28% | — | -36.47% | |
| 37 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.21% | — | — | |
| 38 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.14% | — | — | |
| 39 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.13% | +0.02% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MDGL | Madrigal Pharmaceuticals Inc | +2.6% | — | Unchanged |
| 2 | 2655787D | Blueprint Medicines CORP | +1.5% | NEW | New buy |
| 3 | ALKS | Alkermes plc | +1% | NEW | New buy |
| 4 | ARGX | Argenx Se - Adr | +1% | — | Unchanged |
| 5 | APLSUSD | Apellis Pharmaceuticals Inc | +0.9% | +10.00% | Add |
| 6 | VERA | Vera Therapeutics Inc | +0.6% | +30.17% | Add |
| 7 | QURE | uniQure N.V. | +0.5% | NEW | New buy |
| 8 | ETNBGBP | 89bio Inc | +0.5% | NEW | New buy |
| 9 | ARWR | Arrowhead Pharmaceuticals In | +0.4% | +25.00% | Add |
| 10 | SEPN | Septerna Inc | +0.4% | NEW | New buy |
| 11 | ITCIEUR | Intra-cellular Therapies Inc | +0.4% | — | Unchanged |
| 12 | ✓ | Merus N V | +0.3% | +56.83% | Add |
| 13 | RCKT | Rocket Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 14 | OLMA | Olema Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 15 | MLTX | Moonlake Immunotherapeutics | +0.1% | — | Unchanged |
| 16 | WHWK | Whitehawk Therapeutics Inc | 0% | — | Unchanged |
| 17 | SLNOEUR | Soleno Therapeutics Inc | — | +15.77% | Add |
| 18 | MNKD | Mannkind CORP | — | — | Unchanged |
| 19 | ✓ | Insmed Inc | — | EXIT | Sold out |
| 20 | NGNE | Neurogene Inc | 0% | EXIT | Sold out |
| 21 | GLUE | Monte Rosa Therapeutics Inc | 0% | -24.96% | Trim |
| 22 | OCUL | Ocular Therapeutix Inc | -0.1% | — | Unchanged |
| 23 | BCRX | Biocryst Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 24 | TSHA | Taysha Gene Therapies Inc | -0.1% | +7.24% | Add |
| 25 | CGON | Cg Oncology Inc | -0.1% | — | Unchanged |
| 26 | XENE | Xenon Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 27 | RARE | Ultragenyx Pharmaceutical In | -0.2% | — | Unchanged |
| 28 | KYMR | Kymera Therapeutics Inc | -0.2% | +14.44% | Add |
| 29 | TRML | Tourmaline Bio Inc | -0.2% | — | Unchanged |
| 30 | IOVA | Iovance Biotherapeutics Inc | -0.2% | -17.45% | Trim |
| 31 | SRPT | Sarepta Therapeutics Inc | -0.3% | — | Unchanged |
| 32 | SYRE | Spyre Therapeutics Inc | -0.3% | EXIT | Sold out |
| 33 | AUTL | Autolus Therapeutics PLC | -0.3% | -19.72% | Trim |
| 34 | DYN | Dyne Therapeutics Inc | -0.3% | EXIT | Sold out |
| 35 | AM6 | Amicus Therapeutics Inc | -0.5% | — | Unchanged |
| 36 | PCVX | Vaxcyte Inc | -0.6% | — | Unchanged |
| 37 | SNDX | Syndax Pharmaceuticals Inc | -0.7% | -41.49% | Trim |
| 38 | KURA | Kura Oncology Inc | -0.7% | -36.47% | Trim |
| 39 | BMRN | Biomarin Pharmaceutical Inc | -0.7% | -28.24% | Trim |
| 40 | ASND | Ascendis Pharma A/S | -0.9% | +2.29% | Add |
| 41 | KRYS | Krystal Biotech Inc | -1.1% | +0.25% | Add |
| 42 | UTHR | United Therapeutics CORP | -1.2% | -3.45% | Trim |
| 43 | RNAGBP | Avidity Biosciences Inc | -1.5% | +9.09% | Add |
According to official SEC Form 13F filings, Avoro Capital Advisors LLC reported a total U.S. public equity portfolio value of $11.1B across 39 disclosed positions in Q4 2024.
During Q4 2024, Avoro Capital Advisors LLC's top holdings by market value included UTHR (13.8%)、ARGX (10.8%)、ASND (9.9%). The largest single position, UTHR, represented 13.8% of total portfolio value.
In Q4 2024, Avoro Capital Advisors LLC made 28 total portfolio adjustments, initiating 7 new buys, adding to 10 positions, trimming 7 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.